AZR Stock Forecast: Azora Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$3.85
−0.77% on the day

The median 12-month analyst price target for Azora Therapeutics, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 16 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$55.0M
Ticker Nerd rank
16/ 100
Median analyst target
$12
Analysts covering
4
Revenue$0.0
Operating income−$52.0M
Net income−$52.0M
Free cash flow−$6.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.9%
1M
+0.8%
YTD
−30.0%
1Y
−48.7%
From 52W high
−53.3%
From 52W low
+183.1%
$1.36
$8.25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Azora Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
16/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
70
Volatility
44
Momentum
43
Value
34
Growth
25
Revisions
21
Quality
13
Issuance
2

Accruals (70): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

AZR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AZR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26AZRHigh $14Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$6
Low
$12
Median
$14
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Nov 2026Jones TradingInitiatesBuy$14
3 Aug 2026Alliance Global PartnersInitiatesBuy$11
15 June 2026LUCID CAPITAL MARKETSInitiatesBuy$6.00
30 Sept 2025Maxim GroupUpgradeBuy—
14 Nov 2024Rodman & RenshawInitiatesBuy—
12 July 2023Brookline CapitalReiteratesBuy—
11 July 2023Brookline CapitalReiteratesBuy$6.00
17 Aug 2022Maxim GroupDowngradeHold—
13 Oct 2021Brookline CapitalInitiatesBuy—
29 June 2021Litchfield HillsInitiatesBuy—
7 May 2015MacquarieUpgradeNeutral$55 → $70

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for AZR.

Market Radar

This page is one stock. Monday covers all of them.

AZR appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

AZR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Azora Therapeutics, Inc. returned −48.7% against +6.9% for the S&P 500, dividends included.

AZR vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26AZRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AZR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−40.0%

Higher than 10% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Azora Therapeutics, Inc. has a market value of $55.0M and an enterprise value of $71.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$57.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$11.1M.

  • Shares outstanding: 14.3M.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

AZR and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AZRAzora Therapeutics, Inc.$55.0M16
OKYOOKYO Pharma Ltd.$55.0M26
AVXLAnavex Life Sciences Corp.$54.8M20
BOLDBoundless Bio, Inc.$54.8M93
CHRSCoherus Oncology, Inc.$55.3M38
CGTXCognition Therapeutics, Inc.$55.4M47
NORDNordicus Partners Corp.$54.4M25

Take a look at AZR’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Azora Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about AZR

What is the AZR stock price forecast for 2026-2027?

The median 12-month analyst price target for Azora Therapeutics, Inc. is $12, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AZR stock a buy right now?

Of the 4 analysts covering Azora Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Azora Therapeutics, Inc. 16 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AZR?

As at 21 Nov 2026, Azora Therapeutics, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (70 of 100).

Will AZR stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $12, and Ticker Nerd's factor model ranks Azora Therapeutics, Inc. 16 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AZR stock forecast for 2030?

No analyst covering Azora Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AZR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.

How has AZR stock performed over the past year?

Azora Therapeutics, Inc. returned -48.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Azora Therapeutics, Inc. do?

Azora Therapeutics, Inc. is a biopharmaceutical company developing small-molecule therapies for serious inflammatory and autoimmune diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis.

Company

About Azora Therapeutics, Inc.

Azora Therapeutics, Inc. is a biopharmaceutical company developing small-molecule therapies for serious inflammatory and autoimmune diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis. The compound is designed to activate therapeutic pathways locally in the colon while limiting systemic exposure, reflecting the company’s focus on targeted treatment approaches for gastrointestinal inflammation. Azora’s research platform centers on proprietary aryl hydrocarbon receptor agonists, with potential applications across gastroenterology and other inflammatory disease areas. The company also maintains a focus on dermatology-related indications within the broader autoimmune and inflammatory disease market. Through drug discovery and clinical development, Azora Therapeutics, Inc. participates in the biopharmaceutical sector serving patients with chronic inflammatory conditions and addressing demand for orally administered, mechanism-based therapies. Its activities are centered on advancing proprietary drug candidates rather than marketing an established portfolio of commercial medicines.

CEO Mr. Cary John Claiborne MBA · United States · https://www.azoratherapeutics.com